New treatment for follicular lymphoma that has returned or not improved
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new injection (TQB2825) against standard immunotherapy for people with follicular lymphoma that has come back or hasn't responded to at least two previous treatments. The goal is to see if it can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You have been diagnosed with follicular lymphoma (grades 1-3a) and your cancer cells are CD20 positive.
- You have had at least two prior treatments for your lymphoma, and your cancer has progressed or not responded to the most recent one.
- You have at least one measurable tumor on a CT scan (lymph node >15mm or other site >10mm).
- You are generally able to care for yourself (ECOG 0-2) and expected to live more than 6 months.
- You are willing to use effective contraception if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This study tests a new investigational drug called TQB2825, given as a shot under the skin, for people with certain types of lymphoma that have not responded to previous CD20-targeted treatments. The goal is to see if the drug is safe and effective, and it might help control the cancer.
This study tests a new experimental drug called SCTB35 for people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is designed to target a protein on cancer cells (CD20) and may help your immune system fight the lymphoma.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.